Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
367 stopped studies mapped to Head and Neck Carcinoma and descendants · 94% state a reason
Over the 367 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05003856 | Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule | N/A | terminated | Aug 12, 2021 | M.D. Anderson Cancer Center | Administrativley Complete, 75%\<Participants | Other (stated, no rule matched) |
| NCT05452408 | Antitumor-B KAC PK Study | Phase 1 | withdrawn | Jul 11, 2022 | Medical College of Wisconsin | Study abandoned. | Other (stated, no rule matched) |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early Phase 1 | terminated | Jul 11, 2016 | Wake Forest University Health Sciences | Study closed prior to meeting enrollment goal and funding issues | Enrollment / accrual |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03727061 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care… | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With… | Phase 2 | withdrawn | Feb 24, 2023 | Replimune, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Phase 1 | terminated | Jul 10, 2020 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell… | Phase 1 | terminated | Aug 6, 2020 | Shattuck Labs, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Sep 26, 2023 | Alentis Therapeutics AG | Reprioritization of Trial | Other (stated, no rule matched) |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and… | Phase 2 | terminated | Nov 14, 2019 | University of Utah | Insufficient funding | Funding |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT06199453 | The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a…(LuRM_ACC/2023) | Phase 2 | withdrawn | Jan 10, 2024 | Maria Sklodowska-Curie National Research Institute of Oncology | Administrative reasons | Other (stated, no rule matched) |
| NCT05457478 | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients… | N/A | terminated | Jul 14, 2022 | OHSU Knight Cancer Institute | PI departure | Other (stated, no rule matched) |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr… | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Atara Biotherapeutics | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review… | Safety / toxicity |
| NCT04220775 | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or… | Phase 1 / Phase 2 | terminated | Jan 7, 2020 | M.D. Anderson Cancer Center | The sponsor decided to no longer develop the drug and stop support of studies using the drug. | Sponsor / business decision |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Phase 1 | terminated | Mar 12, 2021 | Molecular Templates, Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | Phase 2 | terminated | May 15, 2017 | University of California, San Francisco | Low accrual | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local…(IMvoke010) | Phase 3 | terminated | Mar 2, 2018 | Hoffmann-La Roche | Decision to terminate the study as its primary endpoint of investigator-assessed event free… | Safety / toxicity |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | Phase 1 | withdrawn | Apr 10, 2024 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or… | N/A | withdrawn | Oct 11, 2021 | OHSU Knight Cancer Institute | study staff transition | Other (stated, no rule matched) |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in… | Phase 1 | terminated | Dec 9, 2020 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Difficult to recruit subjects | Enrollment / accrual |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT03602066 | Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Study terminated by pharmaceutical company | Sponsor / business decision |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant… | Phase 1 | withdrawn | Jul 25, 2022 | Ikena Oncology | Sponsor Decision | Sponsor / business decision |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for…(NPC) | N/A | terminated | Jan 3, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for… | N/A | terminated | Feb 8, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant,… | Phase 1 | terminated | Nov 10, 2020 | Washington University School of Medicine | Ipsen bought out Epizyme | Other (stated, no rule matched) |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | Phase 2 | terminated | Mar 31, 2020 | Vanderbilt-Ingram Cancer Center | Funding ended | Funding |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 4, 2025source: clinicaltrials